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LONGITUDINAL STUDY BASED ON ADMINISTRATIVE  
CLAIMS DATABASE
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OBJECTIVES: Multiple myeloma (MM) is a malignancy of plasma cells that results         
in an overproduction of light and heavy chain monoclonal immunoglobulins. Multiple 
myeloma imposes a signiﬁcant economic and humanistic burden on patients and 
society. The present study is aimed to assess the burden of multiple myeloma in        
epidemiologic and economic terms. METHODS: A retrospective, naturalistic longi-   
tudinal study on the occurrence, outcomes and cost of multiple myeloma using an 
administrative database was performed. We selected residents of a North-eastern      
Region of Italy, who had the multiple myeloma ﬁrst hospital admission during the       
period 2001–2005, and we followed them up until December 31, 2006, death or 
transfers. Direct medical costs were quantiﬁed in the perspective of the Regional 
Health Service. RESULTS: out of a population if 1.2 million inhabitants, we enrolled 
517 patients (52% female) leading to a crude incidence of 8.6/100.000 person-years. 
During the period of observation, 364 (70.4%) subjects died. Total health care costs 
per patients over the maximum of follow-up were a78,020 for the subjects younger 
than 70 years old and a23,096 in older group. CONCLUSIONS: The overall cost of 
MM is substantial, particularly in the ﬁrst year after diagnosis and for hospital care. 
The natural history of the disease requires a great absorption of resources in the early 
phases after diagnosis and in the late stages of the disease. Multiple myeloma imposes   
a signiﬁcant epidemiologic and economic burden to the healthcare- system and 
society.
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A DESCRIPTIVE ANALYSIS OF THE ASSOCIATION BETWEEN BREAST 
CANCER RISK, BONE MINERAL DENSITY AND FRACTURES IN POST-
MENOPAUSAL WOMEN IN THE CANADIAN MULTICENTRE 
OSTEOPOROSIS STUDY
Ioannidis G1, Adachi J1, Burge RT2, Papadimitropoulos M3, Krege JH2, Stock JL2, Muram 
D2
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OBJECTIVES: To explore potential correlations among risk factors for breast cancer, 
bone mineral density (BMD) and fractures in post-menopausal women (PMW). 
METHODS: A cohort of PMW aged 50–85 without breast cancer history (BC) was 
obtained from the Canadian Multicentre Osteoporosis Study (CaMos) database, a 
prospective and longitudinal cohort study following subjects for 10 years. Cross-tabu-
lations were calculated between baseline 5-year breast cancer risk score quartiles (Gail 
scores) and baseline family history of cancer (breast, ovarian, prostate), age group, 
incident breast cancer (during follow-up), fracture (any minimal trauma, or vertebral 
fracture based on x-ray), and BMD status (normal, osteopenia, osteoporosis). Another 
cross-tabulation was performed for baseline BMD by incident BC. RESULTS: Gail 
score quartiles for 4,770 PMW were: Q1  1.329; 1.329  Q2  1.581; 1.581  Q3 
 1.968; Q4  1.968; mean  1.77). Among 1,159 PMW with family history of cancer, 
76% had Gail scores in the 3rd (17%) and 4th (59%) quartiles. Older individuals had 
higher Gail scores, as proportions aged 50–59, 60–69, and 70 within Q3 and 
Q4 were 8.5% & 11.7%; 30.3% & 22.4%; and 43.3% & 29.4%, respectively. Nearly 
4% (n  184) had incident BC, and most cases were diagnosed in women with higher 
baseline Gail scores (33% in Q3; 30% in Q4). Almost 27% (1,263) had prevalent 
fracture and these women had higher Gail scores (35% in Q3: 27% in Q4). In PMW 
with baseline osteopenia, 30% were in Q3 and 22% in Q4, while for osteoporosis 
the proportions were 34% and 26%, respectively. Among PMW with incident BC, 
70% had baseline osteopenia (55%) or osteoporosis (15%). CONCLUSIONS: 
The association between risk of breast cancer and fractures in PMW is uncertain. 
Additional analyses adjusting for multiple confounders in this population are needed 
to help improve our understanding of this complex relationship.
PCN32
IMPLEMENTATION OF CLINICAL INTERVENTION REPORTING SYSTEM 
FOR PHARMACISTS
Kamal S
Children Cancer Hospital, Cairo, Cairo, Egypt
OBJECTIVES: To evaluate pharmacy clinical interventions done in the children cancer 
hospital Egypt during the period from July 2007 to March 2009. METHODS: The 
clinical intervention reports were recorded into a database made by the department 
of pharmaceutical services. RESULTS: A total of 362 Pharmacy Clinical interventions 
were recorded(this number constitute only 40% of the daily interventions), 52(14.4%) 
were category A, which is Incomplete prescription (missing: Generic name, drug form, 
strength, dose, duration.....etc.); 58(16%) were category B, which is Irrational pre-
scribing; 39(10.8%) were category C, which is Excessive quantities, Unnecessary 
medication Duplication of therapy; 152 (41.99%) were category D, which is inap-
propriate dosage/route/ﬂow rate/duration of therapy, where from the 152 Intervention 
in category D 65% was Inappropriate dosage, 15% inappropriate ﬂow rate and 20% 
inappropriate duration of treatment; 25 (6.9%) were category E Drug-drug interac-
tions; 8(2.2%) were category F, which is Allergy to a prescribed medicine; 11(3%) 
were category G, which is Drug incompatibilities-Disease e.g. G6PDD-Food -Lab tests; 
14(3.9%) were category H, which is Drug monitoring is needed; 1 Intervention was 
category I, which is Dose adjustment is needed due to renal insufﬁciency and 2 were 
category J which is Dose adjustment is needed due to hepatic insufﬁciency. CONCLU-
SIONS: The 362 Pharmacy clinical interventions were all medical errors that were 
prevented by the pharmacy staff. The major intervention was mainly category D 
regarding inappropriate dosage. The Pharmacy Clinical Intervention database will be 
used now on the ﬂoors, to encourage participation from the pharmacists and increased 
the reporting.
CANCER – Cost Studies
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BUDGET IMPACT ANALYSIS OF DASATINIB IN PATIENTS WITH 
IMATINIB-RESISTANT CHRONIC MYELOID LEUKEMIA (CML) IN BRAZIL
Asano E1, Nita M1, Moellmann-Coelho A2, Rached R1, Donato B3, Rahal E1
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OBJECTIVES: To evaluate the impact, on Brazilian Public Health Care System (SUS) 
budget, of reimbursing for dasatinib for newly diagnosed CML patients who become 
imatinib-resistant. The budget impact analysis is conducted for three consecutive 
years. METHODS: Due to the rapid evolution of the disease, a monthly-cycle Markov 
model incorporating clinical and epidemiological data was developed to determine the 
target population throughout the analysis time. The base case analysis for imatinib-
resistant CML patients compared the costs of imatinib (600–800 mg/day), versus 
dasatinib (100–140 mg/day). Disease progression depended on the best treatment 
response rates taken from START clinical trials. Pharmaceutical costs were obtained 
according to the ofﬁcial price and standard government discounting procedures, but 
alternative costing scenarios were also evaluated. Data sources for the epidemiological 
and treatment regimen distributions input variables include reports from the Brazilian 
National Cancer Institute (INCA) and published literature. Probability sensitivity 
analysis (PSA) was conducted to account for uncertainties of the model. The three-year 
time period was considered adequate as approval of nilotinib in the near future will 
impact the market share structure for imatinib-resistant CML patients for later years. 
RESULTS: Annual incidence of CML was estimated as 1431. Within one year’s time, 
481 CML patients are expected to become imatinib-resistant. In the base case, the 
net budget impact was a savings of about a1,900,000 in 2009 to savings around 
a3,300,000 in 2011, with a total savings of approximately a8,000,000/three years 
time frame. The net impact on the alternative costing scenarios remained negative. 
The acceptability curve generated from the PSA showed a 100% probability of savings 
on the base case. CONCLUSIONS: The inclusion of dasatinib as 2nd line therapy for 
newly diagnosed CML patients who have become imatinib-resistant in Brazil would 
result in increasingly and signiﬁcant savings, even after accounting for uncertainties 
of the model.
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BUDGETARY IMPACT OF ORAL CHEMOTHERAPY: REAL-WORLD DATA 
ANALYSIS FROM PAYERS’ PERSPECTIVES IN BRAZIL
Clark O, Alves AF, Castro AP, Santos FS, Faleiros E, Clark LG, Paladini L, Pegoretti B, 
Engel T
Evidencias Medicas, Campinas, SP, Brazil
OBJECTIVES: In Brazil, health insurance companies (HIC) must offer coverage for 
intravenous chemotherapy drugs (IVCD), but not for oral chemotherapy drugs (OCD). 
We aimed to evaluate the incremental costs and the budgetary impact of the incorpora-
tion of OCD, using real world data. METHODS: We prospectively collected data 
during 2008, on chemotherapy usage in 14 HIC, on a population of 2 million people 
from different regions in Brazil. First we calculated the costs of the IVCD actually 
used. After that, we indentiﬁed which patients would have formal indication for OCD 
either as a substitutive treatment or in association with IVCD. Then, we calculated 
the costs associated with this intervention. Later, the budgetary impact of using OCD 
for eligible patients was totaled. Only drug acquisition costs were taken into account. 
We were conservative and assumed a “worst case scenario” (WCS) approach as the 
base case, therefore skewing results against OCD. RESULTS: During the one-year 
period, 1328 patients that received intravenous chemotherapy also had formal indica-
tion to receive OCD. The cost of the treatment actually done was US$19,630,000. If 
OCD were also used, the incremental cost would be an additional US$5,500,000. The 
relative incremental cost associated with OCD is therefore US$2.75 per capita per 
year or US$0.23 per capita per month, in a WCS. CONCLUSIONS: The budgetary 
impact linked with the adoption of OCD is of US$0.23 per capita per month, in Brazil, 
according to this real world data analysis.
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EVIDENCE-BASED MEDICINE (EBM) AND THE PROFILE OF APPEALS 
FOLLOWING AUDITING IN CHEMOTHERAPY TREATMENTS
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OBJECTIVES: New health technologies and drugs have great impact on costs, mainly 
in cancer treatment. It was previously shown that EBM can be a powerful tool in 
preventing the coverage of experimental treatments. However, it is usual to receive 
appeals contesting the denied coverage. Our goal is to deﬁne the proﬁle of appeals in 
a large health care plan (HP) in Sao Paulo. METHODS: We collected all data on 
billing and contestation relative to chemotherapy treatments performed by this HP 
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during 2008. Appeals were evaluated according to literature sent and justiﬁcations. 
The budgetary impact was measured. RESULTS: A total of 960 chemotherapy bills 
from this HP were evaluated totaling US$1,277,181.12. There was at least one point 
of recommended coverage denial in 471 (49%) either of materials, drugs or the entire 
procedure, representing US$157,965.77. Denial was based on the best available evi-
dence for each treatment. There were 100 appeals (US$47,889.11) following those 
denials, but 75% or US$35,939.53 was not reversed. We observed that contestations 
were more frequent for high cost drugs like Trastuzumab, Gemzar or Rituximab. The 
most frequent complaint was patient weight variation leading to the use of extra vials 
of these drugs, not previously approved. Interestingly, no such request was made for 
low-cost drugs. However, none of these variations resulted in dose increase larger than 
5%, not justifying the waste of nearly all the drug in the vial. In none of these appeals 
was any literature sent. The appeals reversed were basically bureaucratic cases in 
which the coverage was denied based of incorrect form ﬁllings or lack of any 
documentation. CONCLUSIONS: One in four denial appeals was reversed due to 
bureaucratic paper work. None of the other appeals was accompanied by sup- 
portive literature. Appeals are more frequent when high cost drugs are used in the 
chemotherapy.
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EXPECTED ECONOMIC BURDEN OF TREATING ADVANCED SOFT 
TISSUE SARCOMAS WITH TRABECTEDIN IN RUSSIA
Avxentyeva M, Vorobiev P
Moscow Medical Academy named after I.M.Sechenov, Moscow, Russia
OBJECTIVES: To estimate annual expected economic burden (EEB) of treating 
advanced soft tissue sarcomas (STS) with trabectedin in Russia. METHODS: EEB 
of treating advanced STS with trabectedin was calculated in a model in comparison 
with EEB of bevacizumab for metastatic colorectal cancer (CRC) and sorafenib 
for advanced renal cancer (RC). All studied drugs are used for advanced cancer and 
have similar efﬁcacy of expected increase of survival for several months. The model 
was based on the following assumptions: 1) trabectedin is given to patients with a 
new case of STS revealed at advanced stage and resistant to ﬁrst-line therapy; 2) 
according to federal standards of care, bevacizumab is given to 80% of patients with 
a new case of metastatic CRC; and 3) sorafenib is given to all patients with a new 
case of metastatic RC. Number of new cases of advanced cancer was taken from the 
annual report about cancer morbidity and mortality in Russia. Dosing regimens of 
drugs were taken from clinical studies. Prices of bevacizumab and sorafenib were taken 
from RMBC database, price of trabectedin was proposed by the manufacturer. 
RESULTS: EEB of trabectedin was estimated to be 2.3 billion rubles (a. US$76.4 
million) per year, EEB of bevacizumab for metastatic CRC was 16.0–21.3 billion 
rubles (a. 533.1–US$710.8 million), EEB of sorafenib for metastatic RC was 5.8 
billion rubles (US$194.5 million) per year. CONCLUSIONS: EEB of trabectedin is 
less than of some other drugs for advanced cancer with comparable efﬁcacy that have 
already been recommended for use in a health care system. Bevacizumab is included 
into federal standards of care, sorafenib is included into Essential Drug List, that 
means that these drugs should be available to patients. Therefore trabectedin looks 
affordable for the system.
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NUMBER NEEDED TO TREAT (NNT) TO AVOID ONE 
GASTROINTESTINAL STROMAL TUMOUR (GIST) RECURRENCE IN 
BRAZIL. COST COMPARISON AND BUDGET IMPACT ANALYSIS OF 
ADJUVANT TREATMENT WITH IMATINIB
Valentim J1, Coombs J2, Sakano A3, Puty F1
1Novartis Biociências S.A, São Paulo, SP, Brazil, 2Novartis Pharmaceuticals, East Hanover, NJ, 
USA, 3University of São Paulo, São Paulo, SP, Brazil
OBJECTIVES: To calculate the NNT to avoid a recurrence of GIST after resection, 
to compare the cost of adjuvant treatment with imatinib (IM) with the cost of 
recurrence, and to estimate a budget impact from the Brazilian Public Health 
Care System (SUS) perspective. METHODS: Available relative risk reduction at 1 
year from the Z9001 clinical trial and historical rate of recurrence for no adjuvant 
treatment were applied to estimate absolute risk reduction and NNT. Adjuvant 
treatment effect was extrapolated to 3-year period as ongoing trials are investigating 
longer treatment duration (SSG XVIII). A 5-year time horizon was set for cost 
comparison and Budget Impact Analysis (BIA). Incremental Cost to Avoid 
Recurrence (ICAR) was deﬁned as the difference between the cost of adjuvant 
treatment (IM, monitoring) and the cost of recurrence (IM, surgery, monitoring, 
best supportive care). ICAR was applied to adjuvant GIST incidence for BIA. Epide-
miological data (incidence, proportion of resectables); health access, diagnosis 
and expected adjuvant treatment rates were obtained from literature. Resource utiliza-
tion and cost data came from ofﬁcial guideline and administrative databases, literature 
and expert opinion. Costs are reported in 2007 Euros. A 5% discount rate was 
applied. Univariate sensitivity analysis was performed. RESULTS: The NNT to 
avoid a recurrence was estimated at 2.1 based on extrapolated GIST recurrence 
risk proﬁle in Brazil. Cost of adjuvant treatment was a50,298 and the cost of a recur-
rence a61,998. Annual ICAR was a8,725. The annual impact on the Ministry of 
Health budget was 0.01%, which included impact on infrastructure (e.g. monitoring 
costs) of SUS. Results were sensitive to the recurrence rate and adjuvant treatment 
duration. CONCLUSIONS: Considering that imatinib is already reimbursed by 
SUS for metastatic/unresectable GIST, adjuvant therapy for primary GIST represents 
good value for money for the prevention of recurrence, and an annual budget impact 
of 0.01%.
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COST-EFFECTIVENESS AND BUDGET IMPACT ANALYSIS OF USING 
TEMSIROLIMUS COMPARED TO INTERFERON ALPHA IN METASTATIC 
RENAL CELL CARCINOMA
Bonthapally V1, Ghosh S2, Rappaport H1
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OBJECTIVES: The purpose of the study was to evaluate the cost effectiveness and 
budget impact of temsirolimus compared to interferon alpha-2A (IFN) in any given 
population of metastatic renal cell carcinoma (mRCC). METHODS: Economic evalu-
ations were performed from a US managed care perspective over a 30 months period. 
Cost of treatment was the summation of drug’s cost, administration cost, premedica-
tion cost, and cost of associated adverse events. Outcomes measure for economic 
evaluations was progression free life months gained. Cost effectiveness was conducted 
using a Markov state-transition model in TreeAge®. Time dependent transition prob-
abilities were calculated using multistate Kaplan Meier estimators based on clinical 
trial data. An Excel-based budget impact model was developed to compare two sce-
narios, one for the interferon scenario and one for the temsirolimus scenario. Inputs 
were obtained from SEER registry, clinical trial, and US census bureau. Sensitivity 
analyses were performed. RESULTS: The model yielded ICER $8944 per progression 
free life month gained. For a hypothetical managed care plan with 500,000 members, 
the Budget Impact model estimated 33 patients with mRCC. A 75% (n  25) of mRCC 
was eligible to receive ﬁrst line therapy. A 95% (n  24) eligible patients would be 
treated with IFN. Assuming that temsirolimus was available to 12% of eligible patients 
the expected 30 months cost would be US $18215.7 per patient compared 
with $15,557.90 had all patients been treated with IFN alone. CONCLUSIONS: 
Temsirolimus was found not to be dominantly cost effective compare to interferon 
alpha-2A. This ﬁnding is indicative of two challenges: 1) temsirolimus needs to be 
available at a reduced cost; 2) its threshold for cost-effectiveness needs to be adjusted 
according to relative clinical efﬁcacy. The budgetary impact of adding temsirolimus 
to health plan was estimated to be minimal. While its current availability allows new 
treatment options, temsirolimus may be too expensive to use in some managed care 
plans.
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COST OF MANAGING ADVERSE EVENTS IN THE TREATMENT OF FIRST 
LINE METASTASIC RENAL CELL CARCINOMA: BEVACIZUMAB  
INTERFERON ALPHA-2A COMPARED WITH SUNITINIB IN SPAIN
Calderero V1, García-Muro X2, Puente J3, Trigo JM4, Castro AJ5, Martín-Escudero V5, 
Yébenes M6, Casado MA6
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OBJECTIVES: To perform a cost analysis comparing the management of adverse 
events (AEs) and their associated cost in current clinical practice of bevacizumab (BEV) 
 interferon alpha-2a (IFN) versus sunitinib (SUN) in patients with metastatic renal 
cell carcinoma (mRCC) in Spain. METHODS: A decision analytic model was devel-
oped to compare the costs derived from the management of 40 grade 3/4 AEs in 
patients with mRCC, using published data from published trials (BEV      IFN: Escudier 
B. Lancet 2007;370:2103–11. SUN: Motzer RJ. N Engl J Med 2007;356:115–24). 
The analysis was performed from the Spanish public hospitals perspective. Estimation 
of resources used in managing AEs was made through an Expert Panel. Cost evalua-
tion (a, 2009 values) included direct medical costs: outpatient visits, diagnostic and    
laboratory tests, hospitalization stays, surgeries, and medication. Unitary cost data 
were collected from Spanish Data Base of Sanitary Costs 2009 and Catalogue of            
Medicinal Products. RESULTS: Average cost of managing the grade 3/4 AEs per 
patient was a568 for BEVIFN and a940 for SUN. The per patient cost savings of 
a372 when using BEVIFN corresponds to a relative saving of 40% when compared 
to SUN. The main drivers for SUN costs were related to the management of laboratory 
abnormalities, anaemia, mucosal inﬂammation, decline in ejection fraction, diarrhea, 
thrombocytopenia, rash, epistaxis, and vomiting. In comparison, the main costs for 
BEVIFN were associated to the management of gastrointestinal perforation, bleeding, 
proteinuria, venous thromboembolic event, anorexia and anaemia. CONCLUSIONS: 
The costs of managing side effects of SUN treatment are signiﬁcantly greater than 
those for BEVIFN in Spain. When selecting treatment options, the management costs 
of these side effects may be an important factor to consider for health care payers.
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COST-SAVINGS ASSOCIATED WITH BEVACIZUMAB PLUS CISPLATIN 
AND GEMCITABINE (BCG) COMPARED WITH CETUXIMAB PLUS 
VINORELBINE AND CISPLATIN (CVC) IN PATIENTS WITH ADVANCED 
OR RECURRENT NON-SMALL CELL LUNG CANCER (NSCLC)  
IN GERMANY
Heigener D1, Bischoff HG2, Wiesner C3, Aultman R4
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OBJECTIVES: New treatment options for advanced NSCLC can offer improved sur-
vival over standard chemotherapy and should also offer value for money. Bevaci-
zumab, a humanised monoclonal antibody (MAb) against VEGF, plus chemotherapy 
increases progression-free survival (PFS; median 6.8 months) in advanced NSCLC 
